Psilocybin’s ‘efficacy and safety’ for bipolar II depression demonstrated by American medical association study
“12 patients met both response and remission criteria” at the end of a 12-week study period, the trial found, meaning that measures of the diagnosis had dropped by more than half and fell below a minimum threshold. Results… published by the American Medical Association “suggest efficacy and safety” of psilocybin-assisted psychotherapy for treatment of bipolar…
Recent Comments